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ABSTRACT 
Transcatheter aortic valve replacement (TAVR) revolutionized the treatment of severe 
symptomatic aortic stenosis (AS). TAVR is increasingly offered for lower-risk patients. The 
role and place of TAVR in the future treatment of AS is not clear yet. In this review, we 
discuss the long term outlook for TAVR, its challenges and its relationship to conventional 
surgical aortic valve replacement. 
  
Introduction 
Aortic stenosis. Parallel to the ageing of the western population, degenerative valvular 
diseases, and particularly aortic valve stenosis (AS), are becoming increasingly prevalent, 
imposing a significant social and economic burden on the society (1, 2). Besides impairing 
quality of life, severe symptomatic AS ultimately leads to death within a relatively short 
period of time if not treated with valve replacement (3). In this light, the fact that severe 
symptomatic AS was historically under-treated and AS is even under-diagnosed is particularly 
striking (4, 5). The reasons lie in the common belief that some patients with "high-risk" 
features would not profit from surgical aortic valve replacement (SAVR) or simply will not 
survive the stress associated with the operation: the perceived risk of the procedure was 
deemed to be "prohibitive".  
Concept of TAVR. The concept of transcatheter aortic valve replacement (TAVR) involves 
deploying a stent-mounted bioprosthetic valve in the aortic position, utilizing exclusively 
transvascular access with the avoidance of sternotomy and cardiopulmonary bypass. The 
procedure can be performed in a cath lab using fluoroscopy and echocardiographic guidance. 
In contrast to the traditional surgical approach when the diseased valve is excised, during 
TAVR the native aortic valve is compressed between the stent frame and the aortic wall.  
The idea of percutaneous valve implantation dates back to the late 1980s, and is based on the 
pioneering work of Henning Rud Andersen, Philipp Bonhoeffer and Alain Cribier (6-8). Due 
to the fear of procedural complications, the concept of TAVR met limited initial enthusiasm: 
some even termed the idea as the "the most stupid I've ever heard" (9). 
The current role of TAVR in clinical practice. However, following the first successful first-
in-human implant, TAVR revolutionized the treatment of severe AS in only over a decade. 
Firstly, randomized-controlled trials proved the superiority of TAVR over medical therapy 
and over SAVR in patients having prohibitive or high surgical risk (10-13). These data 
formed the basis of guideline recommendations for TAVR in these risk categories, only a few 
years after its initial clinical introduction (14, 15). Consequently, TAVR numbers saw a 
dramatic increase year-by-year, and in some countries with unrestricted TAVR availability, 
the annual number of patients treated for severe AS has been effectively doubled over the past 
decade (16, 17). Recently, evidence supporting the use of TAVR in intermediate-risk patients 
has been established (see Table 1) (18, 19). 
Prosthesis design, access routes and procedural improvements 
Evolution of valve design. Based on primary design, two distinct groups of TAVR valves can 
be identified: they are either (i) "balloon-inflatable", as the original Cribier-Edwards valve 
and later the SAPIEN (Edwards Lifesciences, Irvine, California, US) valve family; or are (ii) 
"self-expandable" as the CoreValve (Medtronic, Minneapolis, Minnesota, US) and its 
successors. The initial concept was the "balloon-inflatable" valve: a prosthetic valve inside a 
metal stent, crimped and mounted on a balloon. To deploy the valve, the balloon must be 
inflated. Quickly following the introduction of the first "balloon-expandable" valves, the idea 
of utilizing "self-expandable" stents not requiring ballooning emerged. This concept makes 
use of the unique properties of nitinol (nickel-titanium alloy): malleable at lower 
temperatures, a nitinol stent regains its original conformation and radial strength at normal 
body temperature.  
Future design directions. The main directions of future design development are (i) to 
decrease the delivery profile (i.e. making the crimped valve thinner), therefore making smaller 
vessels eligible for vascular access, while maintaining the stent's radial strength; and (ii) to 
decrease the likelihood of paravalvular regurgitation. These can be achieved by modifying 
either the size or shape of the stent cells, and extending the sealing skirt or adding additional 
outer sealing to the prosthesis. The third main focus point is to construct a repositionable and 
retrievable valve. To date, almost all available prostheses have this ability, although some are 
reported to suffer from engineering problems necessitating further modifications (20).   
Besides the stent-mounted prostheses, a unique and promising concept was the Direct Flow 
(Direct Flow Medical, Santa Rosa, California, US) valve, utilizing a completely non-metallic 
design. The hollow plastic frame suspending the valve had to be filled with a solidifying 
polymer to permanently fix the prosthesis in the desired position. Unfortunately, despite the 
promising initial results, the company had to cease its activities due to lack of financial 
support and the valve is not available on the market (21). 
Alternative vascular access. The first human implant was performed through the femoral vein 
with transseptal puncture, anterograde aortic valve crossing and deployment (8). Soon the 
more straightforward retrograde approach through the femoral artery gained popularity, and 
became the "gold standard" in clinical practice. However, as some patients have tortuous, 
calcified or simply too narrow ilio-femoral vasculature rendering them unsuitable for 
transfemoral-TAVR (TF-TAVR), the need for an alternative vascular access route is evident. 
Initially, the anterograde transapical approach (TA-TAVR) seemed to be an attractive 
alternative. Later it became obvious that TA-TAVR is associated with an increased risk of 
bleeding, myocardial injury, pulmonary complications and an overall higher risk of post-
procedural mortality when compared to TF-TAVR  (22, 23). Reasons are not perfectly clear 
and might be attributable to the more invasive procedure involving a thoracic incision, to the 
pre-selection of patients (as TA-TAVR is only considered if TF-TAVR is not feasible), or to 
the combination of both. 
Nevertheless, the search continued: the possibility of using the subclavian or axillary artery, 
the ascending aorta, or the carotid artery as an alternative to TF-TAVR had been extensively 
investigated in the past years. Results from the ROUTE registry demonstrate promising 
results with the direct transaortic approach; however this involves a partial sternotomy or a 
mini-thoracotomy (24). Trans-axillary or trans-subclavian TAVR usually requires a surgical 
cut-down, although successful percutaneous cases have been reported (25, 26). Similarly, 
trans-carotid access can be performed safely, even under local anesthesia alone (27).  
An interesting new concept, the trans-caval access with abdominal aortic puncture and 
retrograde valve deployment emerged recently. This approach demonstrated safety and 
efficacy in a relatively large (n=100) series of patients unsuitable for both transfemoral and 
transthoracic valve delivery, and may gain further acceptance in the future (28). 
Despite all of these efforts, the "second best" vascular access route for TAVR is yet to be 
identified. If an alternative access route is needed, this should be determined on a patient-by-
patient basis. 
Procedural improvements. Parallel to the continuous device development, several procedural 
changes have been implemented to further improve TAVR outcomes and decrease the burden 
associated with the procedure. The principal objectives are to perform the procedure (i) under 
local anesthesia and (ii) totally percutaneously. Avoiding general anesthesia during TAVR 
yields better outcomes and reduces the length of in-hospital stay (29). However, this approach 
precludes the routine use of intra-procedural transesophageal echocardiography. Therefore, 
advanced transthoracic echocardiography monitoring or additional non-imaging methods are 
necessary to assess post-procedural aortic regurgitation (30). The use of low-profile or 
balloon-expandable sheaths and advanced vascular closure devices can facilitate totally 
percutaneous TF-TAVR, thereby promoting early mobilization. 
TAVR for everybody? Complications and cost-effectiveness 
Although being less invasive, TAVR is not a procedure without risks and complications 
(Table 2., Table 3.), and in many aspects does not yield better outcomes when compared to 
SAVR. Despite its overall success, several TAVR-related issues are yet to be solved. 
Paravalvular regurgitation. While post-procedural aortic regurgitation (AR) is traditionally 
an unacceptable finding following SAVR, roughly 25% of all patients after TAVR have mild-
or-more, mostly paravalvular AR (31). The main underlying reason is that the diseased, often 
severely calcified native valve and annulus create an uneven surface for valve deployment. 
Although only moderate-to-severe AR is associated with increased early and late mortality 
and the reported incidence is decreasing over the past years, moderate-to-severe AR can still 
be expected around 5% following TAVR, ten times more frequently than after SAVR (19, 
32). The consequences of post-procedural AR are especially important in younger patients, 
and necessitate further procedural and device development. 
Permanent pacemaker need after TAVR. Due to the proximity of the electrical conduction 
system of the heart to the aortic annulus, rhythm disturbances can occur after aortic valve 
replacement, often necessitating permanent pacemaker implantation. Permanent pacemaker 
need after SAVR was around 5% in a large US database, while it is around 10% following 
TAVR according to the TVT registry report (33, 34). Balloon-expandable designs are 
associated with lower pacemaker rates when compared to self-expandable ones (18, 19). In a 
recently developed model, pre-procedural right bundle branch block, shorter membranous 
septum and noncoronary cusp device-landing zone calcium volume were identified as 
predictors of pacemaker need after TAVR with a third-generation balloon-expandable 
prosthesis (35). Of note, pacemaker requirement after TAVR also varies between different 
valve generations, and is influenced by the technique of implantation (36).  
Neurological complications. Aortic valve interventions are associated with increased risk of 
cerebrovascular events. After contemporary SAVR, stroke occurs in 1.5% of patients, while 
the stroke rate following TAVR was 2% in the latest report from the Transcatheter Valve 
Therapy (TVT) registry (31, 37). To overcome the risk of cerebral embolism, several 
intravascular embolic protection devices had been developed in the past years. Although these 
devices are reported to capture embolic debris in 99% of all cases and are clearly beneficial 
from a logical viewpoint, proving their efficacy is not as straightforward statistically (38, 39). 
One of these filters, after obtaining CE mark several years ago, received FDA approval only 
recently (40).    
Besides manifest stroke, subclinical cerebral microembolization is another TAVR-related 
issue. Although more common after TAVR, cerebral microembolization seems to have no 
effect on early or mid-term health-related quality-of-life (41). However, the long-term effects 
on cognitive function are unknown and should be further investigated. 
Subclinical valve thrombosis. Another TAVR-related question to be answered is the 
frequency and clinical impact of subclinical leaflet thrombosis. Traditionally, bioprosthetic 
heart valve thrombosis was believed to be rare. The problem gained wider attention during the 
PORTICO IDE trial (St. Jude Medical, Saint Paul, Minnesota, US): post-procedural CT 
revealed a strikingly high incidence of leaflet thickening and reduced motion, a finding often 
missed by transthoracic echocardiography. Since then, subclinical valve thrombosis was 
reported in various transcatheter and surgical valves. Lack of post-procedural warfarin 
treatment and larger prosthesis size were identified as predictors (42). Further investigations 
linked the phenomenon to post-procedural neurological events and even to the suspicion of 
accelerated prosthesis degeneration (42, 43). Of note, most cases were reversible by initiating 
oral anticoagulants. However, as the clinical significance is not clarified yet, further 
investigations are warranted before revising the recommendations on the optimal 
anticoagulation strategy following TAVR. 
Vascular and access site related complications. Major vascular complications following 
TAVR include iatrogenic aortic dissection or annular rupture, and access site-related vascular 
injury leading to major bleeding (44). Although having completely different clinical impact, 
these are frequently reported as a combined endpoint in clinical trials (11, 13, 18, 19). Access 
site related major vascular complication rates following TAVR are around 1% according to 
the latest report from the TVT registry (34). Suture-based percutaneous vascular closure 
devices and balloon-expandable sheaths are expected to decrease the incidence of access site 
related complications. 
Cost-effectiveness. Besides clinical outcomes, costs and cost-benefit ratios can be important 
factors when choosing a treatment modality, especially in countries with lower healthcare 
budgets. SAVR is associated with different costs when stratified by surgical risk category: the 
higher the predicted risk, the higher the costs that can be expected and vice-versa (45). 
Therefore, although the benefits of TAVR come at an economically acceptable cost in the 
higher-risk groups, this might not be true for lower-risk patients (46, 47). Finally, the 
expected changes in the price of TAVR prostheses can be fundamental influencers of cost-
effectiveness when comparing TAVR versus SAVR.  
TAVR for the young? 
Initially, TAVR was an option reserved mainly for the elderly. Recently, a continuous 
decrease in the "age limit" is observed in clinical practice (17, 34). Of note, clinico-
anatomical characteristics of AS might be different in the lower age group (48). Additionally, 
questions regarding long-term prosthesis durability must be answered before routinely 
offering TAVR for younger patients.  
Bicuspid aortic valves. As bicuspid aortic valves are more prevalent in younger AS patients, 
the feasibility of TAVR in bicuspid AS is of particular importance when decreasing the age 
limit for TAVR (48-50). In contrast to tricuspid valves, bicuspid aortic valves tend to exhibit 
more eccentric and heavy calcification, and TAVR with early-generation devices was 
associated with more frequent aortic root injury and paravalvular AR in bicuspid AS patients 
(51). Notably, complication rates are reported to decrease with the introduction of newer 
devices (51). Further increasing the safety of TAVR in bicuspid AS is an important target of 
future device development. 
Questions regarding durability. Over the past decade, bioprosthetic heart valves became 
increasingly popular in all age groups because of the possibility to avoid long-term 
anticoagulation (37). Surgical bioprostheses, however, are known to have limited long-term 
durability, although some have demonstrated excellent outcomes even after 20 years 
following implantation. Of note, a lower age at surgery is associated with impaired long-term 
results (52).  
As TAVR was introduced into clinical practice only a decade ago, data on durability are still 
in accumulation. Initial reports on mid-term, 5-year results are encouraging: transvalvular 
gradients and the degree of aortic regurgitation remained stable when compared to the 
immediate post-procedural data (53-56). Of note, as until recently TAVR was reserved for 
elderly high-risk patients, the majority died before they could "outlive" their prosthesis. Thus, 
only a small percentage of the original cohorts was alive and available for the freedom from 
structural valve deterioration analyses at five years: less than 20% (86/519) of the original 
cohort in the PARTNER I trial (54). As a result, drawing firm conclusions from the currently 
available data on long-term durability is difficult.  
Additionally, catheter mounted prostheses must be folded – a process called "crimping" – 
when assembling the delivery system. This procedure can potentially damage the leaflets, 
adversely affecting prosthesis' longevity – however this hypothesis is yet to be confirmed. 
Valve-in-valve TAVR. In case of bioprosthetic valve failure, implanting a second 
transcatheter valve into the failing prosthesis seems to be an attractive option. Valve-in-valve 
(ViV) procedures have been carried out successfully in various clinical scenarios: from 
treating degenerated aortic bioprostheses to implanting transcatheter valves into surgical 
mitral annuloplasty rings (57). Naturally. however, implanting a second valve within the 
frame of the previous one creates a smaller orifice and consequently ViV-TAVR yields 
increased post-procedural gradients (58). A lesson learned from experience with surgical 
bioprostheses is that increased post-operative gradients and prosthesis-patient mismatch 
(PPM) adversely affect long-term durability: an association that is even more pronounced in 
younger patients (52). Therefore, treating a failing bioprostheses with ViV-TAVR in a young 
individual may create a vicious circle of increased gradients, PPM, rapid prosthesis 
degeneration and re-interventions. As a conclusion, ViV-TAVR may be a good option for the 
elderly, but is not an optimal solution for the problem of bioprosthesis failure in younger 
patients. 
Bioengineered heart valves. Constructing living heart valves from cell-free, synthetic, 
bioresorbable scaffolds with in situ tissue engineering can play a role in overcoming limited 
bioprosthesis durability. Recently, these valves demonstrated promising early (12 months) 
results in the pulmonary position in vivo (59, 60). However, extensive product development is 
necessary until off-the-shelf bioengineered transcatheter heart valves might become available 
in the future. 
Role of the Heart Team 
A successful TAVR program requires a strong multidisciplinary approach. At least an 
interventional cardiologist, a cardiac surgeon and preferably a specialist of cardiovascular 
imaging as well as a geriatrician should be involved in the shared decision-making process to 
optimize treatment allocation. Performing unnecessary procedures should be prevented when 
invasive treatment is considered futile. The preoperative evaluation should comprise not only 
traditional risk factors, but also more elusive factors including frailty (61). Development and 
use of dedicated TAVR risk-scores complete the multidisciplinary decision-making (62, 63).  
Who should perform TAVR? 
Achieving and maintaining proficiency in an invasive procedure requires practice. To ensure 
patient safety, defining a minimum required annual case load for centers and for individual 
operators is justified. However, no clear-cut minimum TAVR volume requirements have been 
identified so far (64-66). According to expert consensus, performing TAVR is recommended 
only at centers with on-site cardiac surgical facilities (14, 66). However, a debated issue is the 
extent of surgical involvement during the procedure. Two strongly opposing opinions exist: 
some are even questioning the necessity of surgical backup, claiming similar outcomes in 
centers with and without on-site cardiac surgery in registry data (67). On the contrary, some 
are advocating for more active surgical involvement in the procedure and suggest the active 
"re-training" of surgeons in catheter-based techniques and "wire skills". A recent Society of 
Thoracic Surgeons survey reported a high degree of active surgical involvement in 
performing TAVR in the US (68). Although the finding was greeted and encouraged by the 
Society, the debate on the magnitude of surgical involvement in performing TAVR will 
continue. 
Standardized outcome reporting 
Many issues regarding TAVR warrant further investigations. However, if different studies 
would investigate and report different outcomes, comparing and summarizing their results 
would be difficult. Therefore, the use of universal definitions in outcome reporting is of 
paramount importance. The first "Standardized endpoint definitions for Transcatheter Aortic 
Valve Implantation clinical trials" consensus document was published by the Valve Academic 
Research Consortium (VARC) in 2011, defining a wide range of procedure- and prosthesis-
related endpoints. The document was last updated in 2012 and is used extensively both in 
randomized clinical trials and registries (44). 
Future outlook 
In recent years, TAVR rapidly evolved from a bail-out therapy to become an established 
treatment of AS in high-risk patients. Furthermore, the non-inferiority of TAVR over SAVR 
in intermediate-risk patients is also proven (Table 1.) and incorporated into the latest 
guideline recommendations (18, 19, 69). Of note, the vast majority of SAVR patients are in 
the low-risk category (37). As ongoing randomized-controlled trials are already investigating 
TAVR in low-risk patients (clinicaltrials.gov identifiers: NCT02675114, NCT02825134 and 
NCT02701283), results favoring TAVR over SAVR in this risk stratum may fundamentally 
change current clinical practice (Table 4.). 
Still, in some areas TAVR currently yields worse outcomes when compared to SAVR. A ten-
times more frequent paravalvular AR, associated with a proven negative effect on survival, or 
the unclear long-term durability may be justified in high-risk patients, but might preclude 
recommending TAVR in low-risk patients. These issues remain, even if the low-risk trial 
results would favor TAVR over SAVR at 1 or 2 years of follow-up. Only high-quality long-
term follow-up in these trials can give us the definitive answer on the optimal treatment 
strategy in low-risk patients. The role of professional societies and the Heart Team will be 
even more prominent in the future, when translating these trial results into everyday clinical 
practice. 
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Table 1. Primary results of landmark TAVR trials in severe AS 
Trial Mean 
patient 
age 
[years] 
Total 
number of 
patients 
(TAVR / 
SAVR) 
Risk 
category 
Mean 
STS-
PROM 
TAVR 
device 
Primary 
endpoint 
Time 
frame 
for 
primary 
endpoint  
Conclusion 
PARTNER 
1  
Cohort B 
(10) 
83 
358 
(179/179)* 
Extreme 11.5 SAPIEN Death 
1 year 
post-
procedure 
TAVR is 
superior over 
medical 
therapy in 
prohibitive 
surgical risk 
PARTNER 
1  
Cohort A 
(11) 
84 
699 
(348/351) 
High 12 SAPIEN Death 
1 year 
post-
procedure 
TAVR is non-
inferior to 
SAVR in high 
surgical risk 
Medtronic 
CoreValve® 
U.S. Pivotal 
Trial (13) 
83 
747 
(390/357) 
High 7 CoreValve 
All-cause 
mortality 
1 year 
post-
procedure 
TAVR is 
superior over 
SAVR in high 
surgical risk 
PARTNER 
II  
Cohort A 
(18) 
82 
2032 
(1011/1021) 
Intermediate 6 
SAPIEN 
XT 
Non-
hierarchical 
composite 
of death 
and 
disabling 
stroke 
2 years 
post-
procedure 
TAVR is non-
inferior to 
SAVR in 
intermediate 
surgical risk 
SURTAVI 
(19) 
80 
1660 
(864/796) 
Intermediate 4.5 
CoreValve, 
Evolut R 
All-cause 
mortality 
or 
disabling 
stroke 
2 years 
post-
procedure 
TAVR is non-
inferior to 
SAVR in 
intermediate 
surgical risk 
*Comparator was optimal medical therapy 
TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement; STS-PROM, Society of Thoracic 
Surgeons Predicted Risk of Mortality; 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Overview of complication rates in landmark TAVR trials, 30 days post-procedure  
Trial Risk 
category 
30 day 
mortality 
Paravalvular 
AR (≥moderate) 
Permanent PM Stroke or TIA Major 
vascular 
complication 
TAV
R 
SAV
R 
TAVR SAVR TAV
R 
SAV
R 
TAV
R 
SAV
R 
TAV
R 
SAV
R 
PARTNER 
1  
Cohort B 
(10) 
Extreme 5.0% 2.8%* 12% NA* 3.4% 5.0%* 6.7% 1.7%* 16.2% 1.1%* 
PARTNER 
1  
Cohort A 
(11) 
High 3.4% 6.5% 12.2% 0.9% 3.8% 3.6% 5.5% 2.4% 11% 3.2% 
Medtronic 
CoreValve
® U.S. 
Pivotal 
Trial (13) 
High 3.3% 4.5% 9.0% 1.0% 19.8% 7.1% 5.7% 6.5% 5.9% 1.7% 
PARTNER 
II  
Cohort A 
(18) 
Intermediat
e 
3.9% 4.1% 3.7% 0.6% 8.5% 6.9% 6.4% 6.5% 7.9% 5.0% 
SURTAVI 
(19) 
Intermediat
e 
2.0% 1.3% 
3.4%*
* 
0.3%*
* 
25.9% 6.6% 3.4% 5.3% 6.0% 1.1% 
*comparator was optimal medical therapy 
**at discharge  
AR, aortic regurgitation; PM, pacemaker; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve 
replacement; TIA, transient ischemic attack; 
 
 
 
 
 
Table 3. Overview of complication rates in landmark TAVR trials, at the longest available 
follow-up   
Trial Risk category Longest 
available 
follow-up 
Mortality Paravalvular AR 
(≥moderate) 
Stroke or TIA 
TAVR SAVR TAVR SAVR TAVR SAVR 
PARTNER 1 
Cohort B (70) 
Extreme 5 years 71.8% 93.6%* NR NR 16.0%◦ 18.2%◦* 
PARTNER 1 
Cohort A(71) 
High 5 years 67.8% 62.4% NR NR 15.9% 14.7% 
Medtronic CoreValve® 
U.S. Pivotal Trial (72) 
High 3 years 32.9% 39.1% 5.9% 0% 15.2% 21.0% 
PARTNER II 
Cohort A (18) 
Intermediate 2 years 16.7% 18.0% 8.0% 0.6% 12.7% 11.0% 
SURTAVI (19) Intermediate 2 years 11.4% 11.6% 4.9% 0% 10.0% 11.0% 
*comparator was optimal medical therapy 
◦only stroke  
AR, aortic regurgitation; NR, not reported; PM, pacemaker; SAVR, surgical aortic valve replacement; TAVR, transcatheter 
aortic valve replacement; TIA, transient ischemic attack; 
 
 
 
Table 4. Ongoing Low Risk Trials comparing TAVR and SAVR* 
Trial clinicaltrials.go
v identifier 
Desig
n 
STS-
PRO
M 
 
TAVR 
device 
Estimated  
total 
enrollmen
t 
Primary 
endpoint 
Time 
frame 
for 
primary 
endpoint 
Estimated 
completio
n date for 
primary 
endpoint 
PARTNE
R 3 
NCT02675114 RCT <4% SAPIEN 3 1328 
Composite 
rate of all-
cause 
mortality, all 
stroke, and re-
hospitalizatio
n 
1 year 
post-
procedur
e 
October 
2018 
Medtronic 
Low Risk 
Trial 
NCT02701283 RCT <3% 
CoreValv
e / Evolut 
R 
1200 
All-cause 
mortality or 
disabling 
stroke 
2 years 
post-
procedur
e 
March 
2018 
NOTION 
2 
NCT02825134 RCT <4% 
Any CE 
approved 
TAVR 
device 
992 
Composite 
rate of all-
cause 
mortality, 
myocardial 
infarction and 
stroke 
1 year 
post-
procedur
e 
June 2020 
TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement; RCT, randomized-controlled trial; 
CE, Conformité Européene; STS-PROM,  
*source: www.clinicaltrials.gov 
